Naveen Kumar

@naveen_1282

Rajasthan

3+ Years of experience

SEBI Registration INH000011088

I'm Naveen Kumar, with 9 years of market experience backed by a Master of Business Administration in Finance. Based in Rajasthan, I'm a value investor for the long term and a technical trader for the short term.

Trade Ideas

305

Opinions

677

Followers

109k

Expertise

Quantitative

Growth

Technical

Index Strategies

Market Commentary

Futures & Options

Technical Analysis

Trade Facts

Total Trades

Missed Trades

Profit Trades

Accuracy

Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 1 hour ago

Alembic gets final approval for Binimetinib

Alembic Pharmaceuticals Limited (NSE: APLLTD) has received final USFDA approval for generic Binimetinib tablets in 15 mg and 45 mg strengths. The product has an estimated US reference market of US$282 million for the 12 months ended September 2026. Alembic is eligible for 180 days of generic exclusivity and is the sole first applicant for the 45 mg strength. This is positive for Alembic's US generics business. The specialised oncology product provides an early-entry opportunity and could support revenue growth and profitability. However, US$282 million is the reference market, not Alembic's expected revenue. Actual earnings will depend on launch timing, market share, pricing and margins. The company has not disclosed expected sales or product-level profitability. The final approval also needs to be viewed in context: tentative approvals were already announced earlier in 2026. The next important development is commercial launch, not simply the regulatory approval. What to watch: 1. Commercial launch and initial sales. 2. US generics revenue growth and operating margins. 3. Evidence of sustained product contribution after the initial exclusivity period. View: very positive. The approval is a positive business development,

shared an insight ⚡️ 19 hours ago

KP Green Engineering proposes ₹100 crore promoter warrants

KP Green Engineering Limited (BSE: 544150) has proposed issuing 34.25 lakh convertible warrants to promoter Dr. Faruk G. Patel at ₹292 each. The maximum issue size is approximately ₹100 crore, subject to shareholder and regulatory approvals. The promoter's participation is a positive funding signal. However, the financial results make this announcement more complicated than a straightforward promoter-investment story. H1 FY27 revenue increased 28% to ₹679 crore, but EBITDA grew only 17% to ₹119 crore. PAT declined 41% to ₹34 crore. EBITDA margin fell from approximately 19.2% to 17.5%. The balance sheet also needs attention. Debt increased from ₹196 crore to ₹447 crore, while operating cash flow turned negative at ₹110 crore. The company has expanded its fixed-asset base substantially, but investors need evidence that this investment is generating adequate returns. The warrant issue will bring in ₹25 crore at allotment and the remaining ₹75 crore only if the promoter exercises the warrants. Full conversion would increase the promoter's stake from 57.87% to approximately 60.57%, while diluting existing shareholders by around 6.4% of the enlarged share capital. The key risk is that capital is being raised while profitability and cash conversion are weakening. Investors should not confuse promoter participation with proof that the business is already generating strong returns on its expanded asset base. What to watch 1. Shareholder approval at the 11 December 2026 EGM. 2. Actual warrant allotment and receipt of the upfront ₹25 crore. 3. Recovery in EBITDA margin, PAT and operating cash flow, alongside stabilisation of debt. Verdict: POSITIVE CONFIDENCE. The promoter's proposed investment is constructive, but the weaker earnings, higher debt and negative operating cash flow warrant caution. A stronger investment case requires evidence that the new capital improves financial health and that expansion translates into sustainable cash generation.

287

shared an insight ⚡️ 13th Nov

Pasupati Acrylon secures ₹334 crore ethanol allocation

Pasupati Acrylon Limited (NSE: PASUPTAC, BSE: 500456) has received an allocation to supply 50,745 KL of ethanol to BPCL, IOCL and HPCL for ESY 2026–27. The estimated allocation value is ₹334 crore, equivalent to about 33% of FY26 company revenue. This is a meaningful development because ethanol is already a major business for Pasupati. The company reported FY26 ethanol revenue of ₹324.22 crore and segment result of ₹34.32 crore before interest and tax. The new allocation is therefore comparable to an entire year of its previous ethanol-segment revenue. The financial benefit will depend on the actual supply schedule, feedstock costs and margins. The ₹334 crore should not be treated as profit or as automatically incremental revenue. The company is also expanding its ethanol capacity from 180 KLPD to 240 KLPD, with an estimated ₹25 crore investment funded through internal accruals. The planned completion is by December 2026. One important risk is industry capacity. The company's annual report itself indicates that Indian ethanol production capacity is ahead of current blending demand. OMC allocations and procurement pricing will remain important determinants of utilisation and profitability. Investors should focus less on the headline order value and more on whether the company converts this allocation into higher ethanol sales, sustainable margins and operating cash flow. If execution is strong, the ethanol business can become an increasingly important earnings contributor. What to watch 1. Quarterly ethanol revenue and segment profitability. 2. Progress on the 240 KLPD capacity expansion. 3. Actual supply volumes and operating cash flow during ESY 2026–27. Verdict: BEST NEWS . The allocation is significant and positive for business visibility

417

How can I follow Naveen Kumar's latest investment insights?

You can follow Naveen Kumar's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is Naveen Kumar's investment strategy?

Naveen Kumar follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has Naveen Kumar been a SEBI-registered Research Analyst (RA)?

Naveen Kumar has been a SEBI-registered Research Analyst and have 3+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see Naveen Kumar's past performance and stock picks?

You can check Naveen Kumar's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact Naveen Kumar for stock market advice?

For stock market guidance from Naveen Kumar, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is Naveen Kumar's track record in predicting market movements?

Naveen Kumar has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for Naveen Kumar?

Naveen Kumar is a SEBI-registered Research Analyst with the SEBI Registration INH000011088. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.

Be Financially Free with StockGro